Reference
Kao H-F, et al. Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. BMC Cancer 22: No. 1, 28 Dec 2022. Available from: URL: http://doi.org/10.1186/s12885-022-10343-7
Rights and permissions
About this article
Cite this article
Afatinib/pembrolizumab. Reactions Weekly 1940, 21 (2023). https://doi.org/10.1007/s40278-023-31879-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-31879-0